Disease Studies

RowAnalytics becomes PrecisionLife in exciting rebrand

24/11/19

Oxford, UK – Building on its guiding principles of insight and innovation, AI-enabled precision medicine company RowAnalytics Ltd has undertaken a comprehensive rebrand to become PrecisionLife Ltd, culminating in the launch of a new website and early-stage partnering model.


The company’s core platform is a radical new approach to complex disease analysis, stratifying patients based on their genomic, phenotypic and clinical data. The powerful platform provides unique insights into the combinatorial signatures driving complex diseases such as ALS, Alzheimer’s disease, asthma and breast cancer. PrecisionLife stratifies patient populations with unprecedented detail and uses this knowledge to identify and validate novel targets, biomarkers and drug discovery and repurposing candidates. The company is engaged in discovery and delivery of innovative precision medicine opportunities in multiple areas of unmet medical need.

Working with pharma and biotech, healthcare and disease charities, PrecisionLife operates a scalable early-stage partnering model to develop and out-license multiple novel in vitro/in vivo validated assets with comprehensive supporting biological data packages. These assets are fully annotated and pre-selected to meet known drug discovery and drug repurposing criteria. With offices in the UK, USA, Denmark and Poland, the company is well-positioned to collaborate on an international scale.

Dr Steve Gardner, PrecisionLife co-founder and CEO, commented: “This rebrand comes at a very exciting time for the company. As we expand our portfolio of validated assets, we felt it was time to consolidate our branding and ensure our website effectively showcases our capabilities, value and impact for the life sciences and healthcare markets.”

Dr Veronique Bouchet, PrecisionLife CMO and recently featured as one of the “50 Movers & Shakers in BioBusiness 2019”, commented: “The decision to adopt the PrecisionLife brand across the company was driven by the dynamic, fast-moving nature of the AI sector and our position at the forefront of delivering precision medicine. Our new brand identity and website reflect this and I am excited about our next phase of growth.”

For more information please contact us.


Keep in touch

Please enter your email address if you would like to be kept informed of our work here at PrecisionLife. Note that our Privacy Policy and Terms & Conditions apply.

  • This field is for validation purposes and should be left unchanged.

Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


UK

Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ

USA

1 Broadway Fl 14
Cambridge
MA 02142-1187

Denmark

Agern Allé 3
DK-2970
Hørsholm

Poland

CIC Ul
Chmielna 73m
00-801 Warszawa

  • This field is for validation purposes and should be left unchanged.